Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia.

Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, Lieberman JA, Meltzer HY, Remington G, Kennedy JL.

J Psychiatr Res. 2013 Nov;47(11):1760-5. doi: 10.1016/j.jpsychires.2013.07.025. Epub 2013 Sep 6.

PMID:
24018103
2.

Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia.

Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B.

Mov Disord. 2010 Dec 15;25(16):2809-17. doi: 10.1002/mds.23377.

PMID:
20939080
3.

Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesian Chinese Han patients with schizophrenia.

Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY.

Prog Neuropsychopharmacol Biol Psychiatry. 2012 Apr 27;37(1):106-10. doi: 10.1016/j.pnpbp.2011.12.007. Epub 2011 Dec 29.

PMID:
22227290
4.

Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations.

Utsunomiya K, Shinkai T, Sakata S, Yamada K, Chen HI, De Luca V, Hwang R, Ohmori O, Nakamura J.

Neurosci Lett. 2012 Jan 17;507(1):52-6. doi: 10.1016/j.neulet.2011.11.050. Epub 2011 Dec 6.

PMID:
22172931
5.

Support for association of HSPG2 with tardive dyskinesia in Caucasian populations.

Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B.

Pharmacogenomics J. 2012 Dec;12(6):513-20. doi: 10.1038/tpj.2011.32. Epub 2011 Aug 2.

PMID:
21808285
6.

Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians.

Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, Lieberman JA, Meltzer HY, Kennedy JL.

Eur Neuropsychopharmacol. 2010 Oct;20(10):688-94. doi: 10.1016/j.euroneuro.2010.05.002. Epub 2010 Jun 3.

PMID:
20605420
7.

Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia.

Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J.

Am J Med Genet. 2001 Dec 8;105(8):774-8.

PMID:
11803529
8.

Oxidative stress and tardive dyskinesia: pharmacogenetic evidence.

Cho CH, Lee HJ.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:207-13. doi: 10.1016/j.pnpbp.2012.10.018. Epub 2012 Oct 31. Review.

PMID:
23123399
9.

Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia.

Liou YJ, Chen ML, Wang YC, Chen JY, Liao DL, Bai YM, Lin CC, Chen TT, Mo GH, Lai IC.

Am J Med Genet B Neuropsychiatr Genet. 2009 Mar 5;150B(2):239-42. doi: 10.1002/ajmg.b.30796.

PMID:
18548510
10.

BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.

Miura I, Zhang JP, Nitta M, Lencz T, Kane JM, Malhotra AK, Yabe H, Correll CU.

Schizophr Res. 2014 Feb;152(2-3):365-72. doi: 10.1016/j.schres.2013.12.011. Epub 2014 Jan 7.

11.
12.

Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia.

Basile VS, Ozdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, Macciardi FM, Petronis A, Kennedy JL.

Mol Psychiatry. 2001 Mar;6(2):230-4.

13.

Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia.

Novak G, Gallo A, Zai CC, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, Le Foll B.

Psychiatr Genet. 2010 Feb;20(1):39-43. doi: 10.1097/YPG.0b013e3283351221.

PMID:
20010315
14.

Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia.

Liou YJ, Wang YC, Chen JY, Bai YM, Lin CC, Liao DL, Chen TT, Chen ML, Mo GH, Lai IC.

Psychiatry Res. 2007 Dec 3;153(3):271-5. Epub 2007 Jul 31.

PMID:
17669510
15.

Valbenazine for the treatment of tardive dyskinesia.

Barquero N.

Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review.

PMID:
28276538
16.

Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.

Inada T, Koga M, Ishiguro H, Horiuchi Y, Syu A, Yoshio T, Takahashi N, Ozaki N, Arinami T.

Pharmacogenet Genomics. 2008 Apr;18(4):317-23. doi: 10.1097/FPC.0b013e3282f70492.

PMID:
18334916
17.

No association between dopamine D4 receptor gene -521 C/T polymorphism and tardive dyskinesia in schizophrenia.

Lee HJ, Kang SG, Choi JE, Paik JW, Kim YK, Kim SH, Lee MS, Joe SH, Jung IK, Kim L.

Neuropsychobiology. 2007;55(1):47-51. Epub 2007 Jun 8.

PMID:
17556853
18.
19.

Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.

Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, Lieberman JA, Potkin SG, Kennedy JL.

Int J Neuropsychopharmacol. 2007 Oct;10(5):639-51. Epub 2006 Sep 7.

PMID:
16959057
20.

The interaction of polymorphisms of IL10 and DBH was associated with general symptoms of PANSS with TD in Chinese Han schizophrenic patients.

Sun H, Wang F, Fan H, Yan Q, Cui K, Yuan W, Zhao F, Zhao L, Yuan J, Yang F, Kosten TR, Zhang XY.

PLoS One. 2013 Aug 7;8(8):e70963. doi: 10.1371/journal.pone.0070963. eCollection 2013.

Supplemental Content

Support Center